Ronald R. Buggage

Novagali Pharma SA specializes in research, development and marketing of ophthalmic drugs. Their product pipeline includes products at various stages of development, which address diseases encountered at the three different segment levels of the eye which are surface, anterior and posterior segments. Some of these diseases are dry eye, allergy, glaucoma and retinopathies. Their formulations are based on their technology platforms Novasorb and Eyeject, which optimize bioavailability of drugs as well as safety and comfort for the patient. The company was founded on August 8, 2000 and is headquartered in Evry, France.